A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy

Area of Science:

• Nephrology
• Pharmacology

Background:

• Aldosterone antagonists slow chronic kidney disease (CKD) progression but can cause hyperkalemia, limiting their use with RAS inhibitors.
• A novel non-steroidal mineralocorticoid receptor (MR) blocker, Ly, was investigated for its renoprotective effects.

Purpose of the Study:

• To evaluate the renoprotective efficacy and safety of Ly compared to eplerenone in a rat model of CKD.
• To assess Ly's effects on blood pressure, albuminuria, and kidney function, both as a monotherapy and in combination with losartan.

Main Methods:

• Two protocols using male Munich-Wistar rats with 5/6 renal ablation (Nx).
• Protocol 1: Nx rats treated with vehicle, eplerenone, or Ly.
• Protocol 2: Nx rats treated with losartan alone, or losartan plus eplerenone or Ly.

Main Results:

• Ly demonstrated superior anti-albuminuric and renoprotective effects compared to eplerenone in Protocol 1.
• In Protocol 2, Ly normalized blood pressure and albuminuria when added to losartan, outperforming eplerenone.
• Ly significantly stimulated plasma renin activity (PRA) and aldosterone but did not induce hyperkalemia, despite higher MR affinity than eplerenone or spironolactone.

Conclusions:

• Ly exhibits potent renoprotective effects in a rat CKD model, surpassing eplerenone.
• Ly effectively reduces blood pressure and albuminuria, and prevents CKD progression, even when combined with losartan.
• Ly's ability to block MR without causing hyperkalemia makes it a promising therapeutic candidate for managing CKD.